Wockhardt - Pharmaceutical Contract Manufacturing

Thanks to expert staff, Wockhardt has become a leading global Pharmaceutical Contract Manufacturer. From development to high-volume commercial manufacture, we utilise more than 25 years of contract manufacturing experience to ensure your product is professionally managed all the way to market.

We offer a 'Full Turnkey' value-added service from API production and product development through to scale-up, commercial manufacture and packaging, with global options to maintain a competitive advantage. With a network of 12 facilities strategically located throughout the US, Europe and Asia we aim to provide our cost-effective services where and when you need them. From biotechnology to leading global pharmaceutical companies, Wockhardt is ideally placed to meet your needs.

Our flexible, end-to-end service is redefining manufacture for a range of sterile injectables and other dosage forms. We're also significantly expanding our lyophilisation capabilities to meet global regulatory requirements by investing in two new state of the art sterile facilities in Wrexham, UK and Aurangabad, India (90m2, plus 10m2 existing capacity in the UK to be completed in 2011 and 60m2 of capacity at Wockhardt's Aurangabad facility to be completed during 2009).

Wockhardt gets results fast. From initial agreement to production, our average time to completion of technology transfer is six months. We've even completed some programmes within just two.

We'll work in partnership with you to deliver outstanding product quality, efficiently and reliably through our highly responsive and flexible teams.

Sterile injectable products

Utilising the extensive production facilities at Wockhardt, we have been manufacturing sterile injectable products for our clients for over twenty-five years.

Wockhardt is already partner of choice for the manufacturing of a major new patented US drug. We continue to expand our high quality commercial capabilities in order to meet the growing demand for specialised services.

Wockhardt constantly upgrades it's world class facilities, with a recent four-fold expansion in cartridge manufacturing capacity and ongoing investment in a global-scale biopharmaceutical plant, the Wockhardt Biotech Park. This state of the art Biotech complex has the capacity to cater for 10-15% of global demand for major biopharmaceuticals.

Inspection and Packaging capabilities include fully automatic and semi-automatic visual inspection methods, automatic leak detection, high speed labelling, PVC tray thermoforming & cartoning. Wockhardt has the flexibility to customise primary and secondary packaging options in accordance with client requirements.

Lyophilisation

Wockhardt is significantly investing to upgrade our lyophilisation capabilities, spanning over two continents. We are investing in two new state of the art sterile facilities in Wrexham, UK and Aurangabad, India, ensuring Wockhardt will be ideally placed to meet your demanding market, quality and regulatory requirements.

By the second quarter of 2011, our UK plant will offer a purpose built, fully automated lyophilisation facility. Three new 30m2 freeze-driers will be installed, giving a total of 100m2 of freeze-drying capacity. Utilising the latest technology, the UK facility will offer development, scale-up and commercial scale manufacturing for a range of vial sizes from 2mL to 100mL. Comprehensive, large scale refrigerated storage will also be available for freeze-dried finished product where required.

A virtual walk through of the UK facility will soon be available for our clients to view.

By the first quarter of 2009, 60m2 of lyophilisation capacity will also be available at Wockhardt's Aurangabad facility in India.

Both new facilities will be fully compliant with both FDA and MHRA requirements.

Solid dose products

With over twenty-five years of experience, Wockhardt is equipped with all the expertise necessary to supply quality solid dose formats to our clients. Our Solid Dose facilities provide manufacturing and packing for both plain tablets and film or sugar coated tablets. We also have the capability to provide:

• Press coating (tablet in tablet)
• Sustained release tablets (matrix and enteric coated & granules)
• Sustained release capsules (coated granules / wurster coating)
• Bi-Layer tablets
• Effervescent tablets
• Combined formulations

Our significant experience and solid dose capacity enable us to manufacture small-scale commercial batches on flexible production lines through to high volume products using tried and tested process trains.

Liquids, ointments and creams

The recent acquisition of Pinewood Healthcare in Southern Ireland has expanded Wockhardt's production capabilities for: "Non Beta-Lactam Sachets & Powders (Non-Penicillin Powders) "Oral Liquids and Suspensions" Creams and Ointments.

Established in 1976, Pinewood employs 350-400 people and has exported products worldwide for over 20 years. Pinewood offers a truly professional service to its customers and already partners with a number of multinational clients. Significant investment at the Tipperary manufacturing site has resulted in a first-class, internationally audited, state-of-the-art, facility. The plant has capacity for over 50 million finished packs of product per year.

The in-house research and development division has long-standing expertise in the formulation of liquids, ointments and creams. Purpose built warehousing and expertise in logistics and international documentation complete the picture. Through Pinewood, Wockhardt can deliver competitively priced quality products, delivered on time and backed by individual customer service.

Wockhardt also has four further sites, (two in India and two in France), with manufacturing capabilities in the powders, liquids, ointments and creams sector.

Sachets and powders

The recent acquisition of Pinewood Healthcare in Southern Ireland has expanded Wockhardt's production capabilities for:

• Non beta-lactam sachets & Powders (Non-Penicillin Powders)
• Oral Liquids and Suspensions
• Creams and Ointments

Established in 1976, Pinewood employs 350-400 people and has exported products worldwide for over 20 years. Pinewood offers a truly professional service to its customers and already partners with a number of multinational clients. Significant investment at the Tipperary manufacturing site has resulted in a first-class, internationally audited, state-of-the-art, facility. The plant has capacity for over 50 million finished packs of product per year.

The in-house research and development division has long-standing expertise in the formulation of liquids, ointments and creams. Purpose built warehousing and expertise in logistics and international documentation complete the picture. Through Pinewood, Wockhardt can deliver competitively priced quality products, delivered on time and backed by individual customer service.

Wockhardt also has four further sites, (two in India and two in France), with manufacturing capabilities in the powders, liquids, ointments and creams sector.

Specialised products

With Wockhardt's state of the art sterile injectable facility based in Wrexham in the UK, we are able to offer the manufacture of high potent products (non beta-lactams, cytotoxic products). Wockhardt also has the distinct advantage of being able to handle and process controlled drug substances with its long established UK Home Office license. At the request of the client, Wockhardt is also able to manufacture 'Specials' thanks to its MHRA Specials License.

Wockhardt operates a fully segregated and contained facility dedicated to the manufacture of sterile powdered cephalosporins and designed to meet international regulatory standards. With the facility being located in India, Wockhardt is able to maintain and take advantage of its core competitive advantage.